Outlook Therapeutics, Inc.
OTLK· Nasdaq
OTLKOutlook Therapeutics, Inc.
Filed Aug 14, 2024 · 10-Q · 45 days after period end · 0001558370-24-012234
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Net Income | $44.41M | -$20.68M | -$17.54M | -$12.20M |
| EPS Diluted | -$0.89 | -$1.61 | -$0.08 | -$0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 14, 2024 · 45 d after period end
